1st Circ. Spots 'Gap' In Cancer-Drug Suit Against Karyopharm
By Chris Villani (February 8, 2022, 2:49 PM EST) -- A First Circuit panel appeared receptive Tuesday to claims that Karyopharm Therapeutics Inc. executives gave an overly rosy assessment of negative drug trial results, but questioned whether investors could show the statements were intentional.
During oral arguments, the appeals court weighed a pair of statements by Karyopharm higher-ups claiming the company's cancer-fighting drug, Selinexor, had demonstrated "a predictable and manageable tolerability profile" and touting the success of a so-called STORM study as a "significant step in establishing the efficacy and safety" of the drug.
The investors say claims that Selinexor caused only mild side effects were false. In fact, according to the suit, every...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!